Organogenesis Holdings, Inc. Class A (ORGO)

Organogenesis Holdings, Inc. stock price has experienced volatility in the past six months. The company's shares experienced a significant decline of 28% in January 2026, following a 27% bounce in November 2025. In September 2025, the stock plummeted by 12.39% on a single day, with a further 3.6% drop attributed to negative sentiment across the biotechnology sector. October 2025 saw the stock lose over 19% in the preceding month and continue its downward trend. Earlier in 2025, the first quarter saw a substantial net loss of $18.8 million and a miss on revenue estimates, compounded by consistent revenue declines of 21.20% in May 2025 and 22.40% in August 2025. However, the company reported its Q3 2025 earnings on November 6, 2025, posting an EPS of $0.18, which significantly beat the estimate of $0.07 by 152.86%.

The demand for Organogenesis Holdings, Inc. products and services exhibits some seasonality, with the fourth quarter typically being the strongest for the company.

Organogenesis Holdings, Inc. is a regenerative medicine company focused on developing, manufacturing, and commercializing solutions for advanced wound care, surgical, and sports medicine markets. The company offers a diverse portfolio of bioactive and acellular biomaterials products, including Apligraf, Dermagraft, PuraPly AM, Affinity, Novachor, and NuShield. It also has a cryopreserved suspension, ReNu, in Phase 3 trials for knee osteoarthritis management.

Organogenesis Holdings, Inc. is headquartered in Canton, Massachusetts, with additional offices and manufacturing facilities in San Diego, California, and offices in Birmingham, Alabama, and St. Petersburg, Florida. Internationally, it has offices in Reinach, Switzerland, and all products are manufactured in the United States.

Organogenesis Holdings, Inc. is recognized for its commitment to innovation in regenerative medicine and its mission to improve patient outcomes and reduce healthcare costs. The company emphasizes rigorous scientific research, clinical validation, and strategic partnerships to maintain its position as a leader in the regenerative medicine landscape. While the company has faced financial challenges and stock volatility in the past year, there is no specific information detailing events that have directly impacted its brand reputation in terms of public perception or trust, beyond the general market reaction to its financial performance.

Organogenesis Holdings, Inc. has a diverse ownership structure that includes institutional and individual investors. Major institutional shareholders include Soleus Capital Management, L.P., Morgan Stanley, First Light Asset Management, LLC, Assenagon Asset Management S.A., Vanguard Group Inc, and BlackRock, Inc. Individual investors collectively hold a substantial portion of the company's ownership, and the CEO, Gary S. Gillheeney, Sr., is also a direct shareholder.